Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T60348
(Former ID: TTDI01788)
|
|||||
| Target Name |
Voltage-dependent anion channel (VDAC)
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | Epidermal dysplasias [ICD-11: EK90] | |||||
| Function |
Forms a channel through the mitochondrial outer membrane that allows diffusion of small hydrophilic molecules.
Click to Show/Hide
|
|||||
| BioChemical Class |
Eukaryotic mitochondrial porin
|
|||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
| 1 | VDA-1102 | Drug Info | Phase 2 | Actinic keratosis | [2] | |
| Mode of Action | [+] 1 Modes of Action | + | ||||
| Modulator | [+] 1 Modulator drugs | + | ||||
| 1 | VDA-1102 | Drug Info | [3] | |||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Involvement of voltage-dependent anion channel (VDAC) in dengue infection. Sci Rep. 2016 Oct 25;6:35753. | |||||
| REF 2 | ClinicalTrials.gov (NCT03538951) Study to Evaluate the Efficacy, Safety, and Tolerability of Topical VDA-1102 Ointment in Subjects With Actinic Keratosis (Phase2b). U.S. National Institutes of Health. | |||||
| REF 3 | Clinical pipeline report, company report or official report of Vidac Pharma. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.